Compliance and Oversight. (i) Receiving Party shall ensure that its Advisers abide by the confidentiality obligations of Receiving Party under this agreement.
Compliance and Oversight. Activities are the routine activities and processes conducted by a QHP Issuer, Agent, Broker, or Web-broker as related to ensuring operational integrity, including but not limited to internal reviews and audits of business procedures and processes and maintaining records as required by State or Federal law.
Compliance and Oversight. Activities are the routine activities and processes conducted by a Non-Exchange Entity as related to ensuring operational integrity, including but not limited to internal reviews and audits of business procedures and processes and maintaining records as required by State or federal law.
Compliance and Oversight. 44 A. ACO Compliance Plan 44 B. CMS Monitoring and Oversight Activities 44 C. ACO Compliance with Monitoring and Oversight Activities 45
Compliance and Oversight. ● The Audit Committee shall discuss with management and the external auditors the effect of regulatory and accounting initiatives; ● The Audit Committee shall discuss with management the Corporation’s major financial risk exposures and steps management has taken to monitor and control such exposures; and ● The Audit Committee shall discuss with management and the external auditors any correspondence with regulators or governmental agencies and any employee complaints which raise material issues regarding the Corporation’s accounting policies or financial statements.
Compliance and Oversight. LSO currently meets, and agrees to comply with the current and applicable revisions of: • US 21 CFR 820 Quality System Regulations • ISO 13485/13488 • Other applicable foreign and US federal, state, and local laws, rules, regulations, and orders for medical device manufacture and distribution LSO agrees to maintain, and notify CURON in a timely manner if there is a change in the status, of the following certifications: • US FDA Facility Registration • ISO 13485/13488 Certification • California Medical Device Manufacturing License LSO agrees that CURON, and entities with regulatory oversight of CURON Products (e.g., European Notified Body or Competent Authority, Health Canada Health Product and Food Branch, California Food and Drug Branch, or US Food and Drug Administration), may examine the documentation associated with the Products, and may audit LSO and its subcontractor’s facilities, with reasonable notification and justification. LSO may charge buyer for audits at a rate of $75 per hour. LSO agrees to provide a copy of a regulatory agency audit report (e.g., US FDA 483 or Warning Letter, EU Notified Body Nonconformity Report) to CURON in a timely manner. LSO agrees to contact CURON within 24 hours should a regulatory agency focus its efforts or stated intent upon assessment of CURON Products. LSO agrees to contact CURON of the root cause and corrective action should an internal audit reveal deficiencies in its quality system or facility that directly affects CURON Products. STAFF and MANUFACTURING ENVIRONMENT LSO is responsible for hiring, training, and supervision of LSO manufacturing and quality personnel. The LSO facility consists of areas for receiving, inspection, stores, manufacturing, packaging, and warehousing appropriate for medical devices. LSO will ensure that CURON Products are manufactured in a controlled environmental area that has been qualified to a recognized standard applicable to medical devices, and is periodically monitored for bioburden and airborne particulate levels. Qualification and monitoring reports may be reviewed by CURON as needed.
Compliance and Oversight. As recipient of FTA formula funds, PRTC complies with federal requirements that pass through to the SUBRECIPIENT. To ensure that projects are implemented in accordance with FTA requirements, PRTC will monitor SUBRECIPIENT activity by randomly reviewing documentation including but not limited to A-133 audit or other consolidated and comprehensive financial statements, monthly, quarterly and annual reports, FTA-required documentation of Title VI and DBE compliance, and by conducting site visits at a minimum of once over the life of the project. SUBRECIPIENT is subject to Federal Funding Accountability and Transparency Act (“FFATA”) reporting and must supply required data for entry into the FFATA Subaward Reporting System if applicable.
Compliance and Oversight. 36 Participant Compliance Plan 36 Compliance with Monitoring and Oversight Activities 37 Article XV. Data Sharing and Reports 41 General 41 Provision of Certain De-Identified Data for Quality Improvement and Safety 41 Provision of De-Identified Dashboard and Summary Information 41 Article XVI. Submission of Required Data 42 General 42 Submission Timing and Contents 42 Required Data 42 CMS Quality Reporting Initiatives 42 Article XVII. Certification of Data and Information 43 General 43 Annual Certification 43 Article XVIII. Audits and Record Retention 43 Right to Audit and Correction 43 Maintenance of Records 44 Article XIX. Remedial Action and Termination 44 Remedial Action 44 Termination of the Agreement by the Participant 45 Termination of the Agreement by CMS 46 Notification of ET3 Partners, Downstream Practitioners and Billing Parties 46 Article XX. Limitations on Review and Dispute Resolution 47 Limitations on Review 47 Dispute Resolution 47
Compliance and Oversight. The firm’s President, Xxxxxx Xxxxxx, JD (IACCP), is responsible for the firm’s strategy and administration and oversees the compliance and operations departments. She also leads the onboarding process of new client accounts and heads a team that communicates effectively with accountants, custodians, and administrators during the transition period and for the duration of the relationship.
Compliance and Oversight. The Parties shall observe and comply with all applicable federal, state, and local laws, regulations, and requirements.
